Gates Commits $89m To Novavax After Maternal RSV Vaccine Success
This article was originally published in Scrip
Now that Novavax Inc.'s respiratory syncytial virus (RSV) vaccine has succeeded in a Phase II clinical trial in pregnant women, the Bill & Melinda Gates Foundation has committed up to $89m to help the company fund a massive Phase III trial that will include sites in developing countries.
You may also be interested in...
Sponsors have been increasingly developing vaccine candidates for the respiratory syncytial virus with an unmet need existing for infants; the advisory committee will evaluate FDA's proposed approach for developing candidates in the target population.
Novavax shocked investors with negative results for its RSV vaccine in a Phase III clinical trial immunizing older adults, but promised more data – and ideas for a potential second Phase III trial – in October.
The market for public offerings by biopharma companies is tough, but Corbus Pharmaceuticals, Loxo Oncology and Novavax used three different strategies to raise cash from new and existing shareholders.